News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) And DSM Biologics Announce PER.C6(R) Licensing Agreement With UMN Pharma


3/9/2006 1:18:34 PM

Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6® cell line in its 'UMN-03' project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES